Cirz Ryan T, Romesberg Floyd E
The Scripps Research Institute, La Jolla, California 92037, USA.
Crit Rev Biochem Mol Biol. 2007 Sep-Oct;42(5):341-54. doi: 10.1080/10409230701597741.
Mutation is the driving force behind many processes linked to human disease, including cancer, aging, and the evolution of drug resistance. Mutations have traditionally been considered the inevitable consequence of replicating large genomes with polymerases of finite fidelity. Observations over the past several decades, however, have led to a new perspective on the process of mutagenesis. It has become clear that, under some circumstances, mutagenesis is a regulated process that requires the induction of pro-mutagenic enzymes and that, at least in bacteria, this induction may facilitate evolution. Herein, we review what is known about induced mutagenesis in bacteria as well as evidence that it contributes to the evolution of antibiotic resistance. Finally, we discuss the possibility that components of induced mutation pathways might be targeted for inhibition as a novel therapeutic strategy to prevent the evolution of antibiotic resistance.
突变是许多与人类疾病相关过程背后的驱动力,包括癌症、衰老以及耐药性的演变。传统上,突变被认为是用保真度有限的聚合酶复制大型基因组的必然结果。然而,过去几十年的观察结果为诱变过程带来了新的视角。很明显,在某些情况下,诱变是一个受调控的过程,需要诱导促诱变酶,并且至少在细菌中,这种诱导可能促进进化。在此,我们综述了关于细菌中诱导诱变的已知信息以及它有助于抗生素耐药性进化的证据。最后,我们讨论了诱导突变途径的组成部分可能作为一种预防抗生素耐药性进化的新型治疗策略而被靶向抑制的可能性。